This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): quetiapine fumarate, FK949
Description: BioMedTracker has separate drug profiles for the regular release and extended release (XR) formulationsof Seroquel. Please also see Seroquel XR.
Seroquel (quetiapine fumarate) is an atypical antipsychotic with a higher affinity for the serotonin 5-HT2 receptor relative to its affinity for the dopamine D-2 receptor. Though the exact mechanism is unclear (either due to a difference in affinities for such receptors or fast dissociation from the D-2 receptor), atypical antipsychotics are able to produce an antipsychotic effect (through blockade of D-2 receptors in the ventral striatum) with fewer extrapyramidal motor function side effects (or EPSs, which are caused by blockade of D-2 receptors in the dorsal striatum).
Seroquel tends to generally have a lower affinity for various receptors than other atypical agents, and hence is used at a higher dose. It is an antagonist at the serotonin 5HT1A and 5HT2 (IC50s=717 & 148nM respectively), dopamine D1 and D2 (IC50s=1268 & 329nM respectively), histamine H1 (IC50=30nM), andadrenergic a1 and a2 receptors (IC50s=94 & 271nM,respectively). Seroquel has no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors (IC50s>5000 nM).
Deal Structure: Historical revenue for Seroquel and Seroquel XR through 2014 is recorded under Seroquel. As of Q1 2015, revenues for Seroquel IR are not given and so revenues will only be recorded under the XR profile. Revenue splits for this drug are BioMedTracker estimates. Revenue forecast also includes Seroquel XR.
Seroquel was originally developed by Zeneca. In January 1999, Fujisawa announced that it has concluded a licensing agreement with Zeneca (now AstraZeneca) whereby Fujisawa obtained an exclusive right to market Seroquel in Japan. In Japan, quetiapine fumarate was developed by Zeneca and an application for its registration was filed by them in December 1998. Upon approval, Fujisawa (now part of Astellas) will exclusively market this compound in Japan.
AstraZeneca & Hutchison
In January 2015, Hutchison China Meditech (Chi-Med) announced that Hutchison Whampoa Sinopharm, a subsidiary of Chi-Med, has entered into an exclusive distribution agreement with AstraZeneca to...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc. Hutchison MediPharma Limited
Additional information available to subscribers only: